Media / News Releases
Jan 23, 2020
Amarex Clinical Research, LLC is pleased to announce that a white paper authored by Hana Mekonnen, MS, Senior Vice President of Biometrics for Amarex, was published in the NSF Health Sciences Journal, Issue 46.
Oct 08, 2019
On October 9th, Amarex is pleased to announce that global public health organization NSF International has made majority investment in Amarex. The investment supports both Amarex’s mission of expediting patient access to safe and effective clinical products, and NSF International’s mission of protecting and improving human health, through expanded services to the medical device and pharma/biotech industries. Amarex will be a part of NSF International’s global health science consulting business, and will be referred to as Amarex Clinical Research, LLC, an NSF International company. Amarex founder Dr. Kazem Kazempour, will continue as President and CEO of Amarex under NSF International.
Sep 30, 2019
On September 25th, at the National Taiwan University Hospital (NTUH) in Taipei, Taiwan, Amarex Taiwan COO, Dr. Chia-Hua Maggie Ho, gave a keynote presentation addressing the application of, and current US FDA regulatory trends for, AI/ML-based SaMD. Dr. Ho outlined the potential risks and benefits involved with smart medical device product development, and highlighted how Amarex can help with the regulatory approval process.
Aug 20, 2019
Amarex Clinical Research, LLC is pleased to announce that Taiwan President Tsai Ing-wen attended the opening ceremony for BIO Asia-Taiwan on July 24, 2019 to show her support for Taiwanese expertise and innovation in biotechnology R&D. Amarex Taiwan exhibited services at the conference and Dr. Kazem Kazempour, as well as the company’s COO, Dr. Chia-Hua Maggie Ho, were honored to meet President Tsai at Amarex’s exhibit. The support of the Taiwanese government to the biotech industry in Taiwan indicates a distinct commitment that the people of Taiwan have to this industry, and Amarex is privileged to be a part of this growing piece of Taiwan’s economy.
Jun 12, 2019
Amarex Taiwan, LLC announces today that the US FDA has granted Orphan Drug Designation (ODD) to RP-72, a 72 amino acid proprietary recombinant protein antagonist for the CXCR1 and CXCR2 receptors of interleukin-8, a drug that treats pancreatic cancer. Amarex submitted the ODD application on behalf of its client, Rise Biopharmaceuticals, Inc.
May 13, 2019
Amarex Taiwan, LLC announces that the US FDA has granted Fast Track Designation to a novel monoclonal antibody for use in combination with carboplatin in the treatment of CCR5-positive metastatic triple-negative breast cancer (mTNBC) patients. The FDA granted the designation to the drug sponsor following significant preclinical results demonstrating a greater than 98% reduction in human breast cancer metastasis in preclinical models.
Apr 16, 2019
Amarex Taiwan, LLC learned that, on March 14, 2019, the US FDA approved a new rapid in vitro diagnostic (IVD) kit, Vstrip, for detection of H. pylori infection. Vstrip is a single use immunochromatographic assay for the qualitative detection of H. pylori antigens developed and produced by Panion & BF Biotech Inc. (PBF), a Taiwan-based biopharmaceutical company.